| Name | Title | Contact Details |
|---|
EverZinc is a global leader in producing specialty zinc materials, with a history of over 185 years. Established in 2016, the company became the worlds largest zinc specialty chemical producer after merging with U.S. Zinc in 2022. Headquartered in Houston, Texas, EverZinc operates 14 production sites across North America, Europe, and Asia, employing over 800 people. The company specializes in four main product lines: fine zinc powders, zinc oxide, zinc powders for batteries, and Zano®, an ultra-fine zinc oxide. These products serve various industries, including personal care, pharmaceuticals, chemicals, textiles, agriculture, paints, coatings, and rubber. EverZincs advanced manufacturing technologies and focus on material science support its diverse customer base and contribute to its strong growth in the zinc specialty chemical market.
Bloomer Trailer Mfg Inc is an automotive company based out of P.O. BOX 1191, Salado, Texas, United States.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.